explore -WSS

explore

author：entertainment 2025-09-30 23:39:23 - browse：88

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Obesity drug from Roche shows promise in early study

WSS

Review: 'Barbie' will hit you like a shot in the heart

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

Caitlin Bernard's story shows physicians can't shy from advocacy

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

Fertility clinic egg and embryo storage is a disaster

hotspot

explore

explore

Heart attack and stroke risk calculators need revising

Elizabeth Warren probes abortion access

Jerome Adams on the need for new antivirals for Covid

Cherokee Nation medical school graduates its first class

United colonoscopy coverage change 'may cost lives,' doctors say

AbbVie dramatically boosts its spending on lobbying

Cancer drug shortages should be causing more outrage

Organ transplantation is at a crossroads. Major reform is needed

Activists slam private health insurers over coverage restrictions

How artificial intelligence is being used to detect, treat cancer

Wikipedia

STAT series 'Denied by AI' wins major journalism prizes

Abbott's new stent may help patients with peripheral artery disease

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Fertility clinic egg and embryo storage is a disaster

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

New rules on organ donation and transplantation 'will bring chaos'

leisure time

hotspot

explore

leisure time